Fig. 4From: The change rate in serum nitric oxide may affect lenvatinib therapy in hepatocellular carcinomaPFS and OS in the patients with HCC based on the CSRN. A The median progression free survival in the CSRN and non-CSRN groups in patients with HCC. B The median overall survival in the CSRN and non-CSRN groups in patients with HCCBack to article page